Prof. Nagula Shankaraiah is an accomplished medicinal and synthetic organic chemist with a distinguished record in academics and research. Over the course of his career, he has led numerous research programs focused on the rational design and synthesis of novel chemical entities (NCEs), inspired from both natural and privileged scaffolds as anti-cancer agents. He has made notable contributions for the development of cytotoxic agents targeting critical cancer pathways, including epigenetic regulators and multi-kinase inhibition, tubulin, and topoisomerase II, dual target inhibition such as VEGFR-2, CDKs, HDACs. His research encompasses aspects of modern drug discovery, including structure–activity relationship (SAR) elucidation, hit identification, hit-to-lead progression, and lead optimization. In addition to his expertise in medicinal chemistry, he is also highly proficient in the development of synthetic methodologies. His work integrates sustainable and green chemistry principles, employing state-of-the-art techniques such as click chemistry, one-pot domino transformations, and C–H activation/functionalization. He has also contributed to mechanistic organic chemistry by live ESI/MS and NMR studies. His scientific contributions are reflected in an extensive portfolio of high-impact publications and patents, underscoring his enduring impact in the field of medicinal and organic chemistry.
